Physician profile
Robert Schilz
NPI 1972523538
$355,714.85
in general payments reported to CMS, 2019-2025
43 companies · $81K in 2025
The $81K reported for 2025 was more than what 99% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $7,422 · 2021: $38K · 2022: $60K · 2023: $68K · 2024: $83K · 2025: $81K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $188K · Travel and Lodging: $21K · Consulting Fee: $15K · Food and Beverage: $8,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $188,397.75 |
| Travel and Lodging | $20,599.45 |
| Consulting Fee | $15,441.34 |
| Food and Beverage | $8,182.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $145,511.00 | 2019-2025 | Remodulin, Tyvaso, Orenitram |
| Actelion Pharmaceuticals US, INC. | $137,476.60 | 2019-2025 | Uptravi, Opsumit, Veletri |
| Bayer Healthcare Pharmaceuticals INC. | $36,209.92 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $34,333.95 | 2019-2025 | Winrevair, Keytruda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.97 | 2019-2025 | Jardiance, Ofev |
| Inari Medical, INC. | $192.92 | 2023-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbott Laboratories | $154.80 | 2019-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Sandoz INC. | $153.82 | 2019-2024 | Treprostinil |
| Astrazeneca Pharmaceuticals LP | $146.83 | 2019-2023 | Breztri |
| E.R. Squibb & Sons, L.L.C. | $121.26 | 2019-2025 | Camzyos, Eliquis |
| Astellas Pharma US INC | $102.46 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $101.80 | 2021 | |
| Genentech, INC. | $81.22 | 2019 | |
| Glaxosmithkline, LLC. | $62.87 | 2019-2020 | |
| Insmed, INC. | $55.78 | 2022-2024 | Arikayce |
Show all 41 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Schilz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.